Progression to metastatic stage in a cellular model of prostate cancer is associated with methylation of the androgen receptor gene and transcriptional suppression of the insulin-like growth factor-I receptor gene

Experimental Cell Research

Volumn 316, Issue 9, 2010, Pages 1479-1488

  Schayek, Hagit ^a   Bentov, Itay ^a   Sun, Shihua ^b   Plymate, Stephen R ^b   Werner, Haim ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Androgen receptor; DNA methylation; Epigenetic regulation; Insulin like growth factor I receptor (IGF1R); Prostate cancer

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANDROGEN RECEPTOR; BISULFITE; DNA; FLUTAMIDE; MESSENGER RNA; SOMATOMEDIN C RECEPTOR;

ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CONTROLLED STUDY; CPG ISLAND; DISEASE COURSE; DNA METHYLATION; DNA SEQUENCE; DRUG TARGETING; EPIGENETICS; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MALE; METASTASIS POTENTIAL; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN METHYLATION; TRANSCRIPTION REGULATION;

EID: 77952891110     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2010.03.007     Document Type: Article

References (46)

1. Gelmann E.P. Molecular biology of the androgen receptor. J. Clin. Oncol. 2002, 20:2001-2015.
2. Grossmann M.E., Huang H., Tindall D.J. Androgen receptor signaling in androgen-refractory prostate cancer. J. Natl. Cancer Inst. 2001, 93:1687-1697.
3. Shi X.B., Ma A.H., Xia L., Kung H.J., de Vere White R.W. Functional analysis of 44 mutant androgen receptors from human prostate cancer. Cancer Res. 2002, 62:1496-1502.
4. LeRoith D., Werner H., Beitner-Johnson D., Roberts C.T. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocrine Rev. 1995, 16:143-163.
5. Baserga R., Hongo A., Rubini M., Prisco M., Valentinis B. The D receptor in cell growth, transformation and apoptosis. Biochim. Biophys. Acta 1997, 1332:F105-F126.
6. Werner H., LeRoith D. New concepts in regulation and function of the insulin-like growth factors: implications for understanding normal growth and neoplasia. Cell. Mol. Life Sci. 2000, 57:932-942.
7. Samani A.A., Yakar S., LeRoith D., Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocrine Rev. 2007, 28:20-47.
8. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nature Rev. Cancer 2008, 8:915-928.
9. Baserga R. The insulin-like growth factor-I receptor as a target for cancer therapy. Expert Opin. Ther. Targets 2005, 9:753-768.
10. Chan J.M., Stampfer M.J., Giovannucci E., Gann P.H., Ma J., Wilkinson P., Hennekens C.H., Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998, 279:563-566.
11. Renehan A.G., Zwahlen M., Minder C., O'Dwyer S.T., Shalet S.M., Egger M. Insulin-like growth factor-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004, 363:1346-1353.
12. Tennant M.K., Thrasher J.B., Twomey P.A., Drivdahl R.H., Birnbaum R.S., Plymate S.R. Protein and mRNA for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium. J. Clin. Endocrinol. Metab. 1996, 81:3774-3782.
13. Chott A., Sun Z., Morganstern D., Pan J., Li T., Susani M., Mosberger I., Upton M.P., Bubley G.J., Balk S.P. Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of type 1 insulin-like growth factor receptor. Am. J. Pathol. 1999, 155:1271-1279.
14. Hellawell G.O., Turner G.D., Davies D.R., Poulsom R., Brewster S.F., Macaulay V.M. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res. 2002, 62:2942-2950.
15. Liao Y., Abel U., Grobholz R., Hermani A., Trojan L., Angel P., Mayer D. Up-regulation of insulin-like growth factor axis components in human primary prostate cancer correlates with tumor grade. Human Pathol. 2005, 36:1186-1196.
16. Pandini G., Mineo R., Frasca F., Roberts C.T., Marcelli M., Vigneri R., Belfiore A. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Cancer Res. 2005, 65:1849-1857.
17. Bakin R.E., Gioeli D., Sikes R.A., Bissonette E.A., Weber M.J. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res. 2003, 63:1981-1989.
18. Schayek H., Haugk K., Sun S., True L.D., Plymate S.R., Werner H. Tumor suppressor BRCA1 is expressed in prostate cancer and control IGF1-R gene transcription in an androgen receptor-dependent manner. Clin. Cancer Res. 2009, 15:1558-1565.
19. Baylin S.B., Herman J.G. DNA hypermethylation in tumorigenesis: epigenetics join genetics. Trends Genet. 2000, 16:168-174.
20. Li L.C., Okino S.T., Dahiya R. DNA methylation in prostate cancer. Biochim. Biophys. Acta 2004, 1704:87-102.
21. Baylin S.B., Herman J.G., Graff J.R., Vertino P.M., Issa J.P. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res. 1998, 72:141-196.
22. Li L.C., Zhao H., Shiina H., Kane C.J., Dahiya R. PGDB: a curated and integrated database of genes related to the prostate. Nucleic Acids Res. 2003, 31:291-293.
23. Kinoshita H., Shi Y., Sandefur C., Meisner L.F., Chang C., Choon A., Reznikoff C.R., Bova G.S., Friedl A., Jarrard D.F. Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer. Cancer Res. 2000, 60:3623-3630.
24. Sasaki M., Tanaka Y., Perinchery G., Dharia A., Kotcherguina I., Fujimoto S., Dahiya R. Methylation and inactivation of estrogen, progesterone, and androgen receptors in prostate cancer. J. Natl. Cancer Inst. 2002, 94:384-390.
25. Wu J.D., Haugk K., Woodke L., Nelson P., Coleman I., Plymate S.R. Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J. Cell. Biochem. 2006, 99:392-401.
26. Bae V.L., Jackson-Cook C.K., Brothman A.R., Maygarden S.J., Ware J.L. Tumorigenicity of SV40 T antigen immortalized human prostate epithelial cells: association with decreased epidermal growth factor receptor (EGFR) expression. Int. J. Cancer 1994, 58:721-729.
27. Bae V.L., Jackson-Cook C.K., Maygarden S.J., Plymate S.R., Chen J., Ware J.L. Metastatic sublines of an SV40 large T antigen immortalized human prostate epithelial cell line. Prostate 1998, 34:275-282.
28. Frommer M., McDonald L.E., Millar D.S., Collis C.M., Watt F., Grigg G.W., Molloy P.L., Paul C.L. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:1827-1831.
29. Plymate S.R., Tennant M.K., Culp S.H., Woodke L., Marcelli M., Colman I., Nelson P.S., Carroll J.M., Roberts C.T., Ware J.L. Androgen receptor (AR) expression in AR-negative prostate cancer cells results in differential effects of DHT and IGF-I on proliferation and AR activity between localized and metastatic tumors. Prostate 2004, 61:276-290.
30. Li L.C., Chui R., Nakajima K., Oh B.R., Au H.C., Dahiya R. Frequent methylation of estrogen receptor in prostate cancer: correlation with tumor progression. Cancer Res. 2000, 60:702-706.
31. Lau K.M., LaSpina M., Long J., Ho S.M. Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Res. 2000, 60:3175-3182.
32. Singal R., van Wert J., Bashambu M. Cytosine methylation represses glutathione S-transferase P1 (GSTP1) gene expression in human prostate cancer cells. Cancer Res. 2001, 61:4820-4826.
33. Kuzmin I., Gillespie J.W., Protopovov A., Geil L., Dreijerink K., Yang Y., Vocke C.D., Duh F.-M., Zabarovsky E., Minna J.D., Rhim J.S., Emmert-Buck M.R., Linehan W.M., Lerman M.I. The RASSF1A tumor suppressor gene is inactivated in prostate tumor and suppresses growth of prostate carcinoma cells. Cancer Res. 2002, 62:3498-3502.
34. Fiori A.R., Steinhoff C., Muller M., Seifert H.H., Hader C., Engers R., Ackermann R., Schulz W.A. Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br. J. Cancer 2004, 91:985-994.
35. Kang G.H., Lee S.W., Lee H.J., Hwang K.S. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J. Pathol. 2004, 202:233-240.
36. Vu T.H., Hoffman A. Alterations in the promoter-specific imprinting of the IGF-2 gene in Wilms' tumor. J. Biol. Chem. 1996, 271:9014-9023.
37. Steenman M.J., Rainier S., Dobry C.J., Grundy P., Horon I.L., Feinberg A.P. Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumor. Nature Genet. 1994, 7:433-439.
38. Wutz A., Smrzka O.W., Schweifer N., Schellander K., Wagner E.F., Barlow D.P. Imprinted expression of the Igf2r gene depends on an intronic CpG island. Nature 1997, 389:745-749.
39. Culig Z., Hobisch A., Cronauer M., Radmayr C., Hittmair A., Zhang J., Thurnher M., Bartsch G., Klocker H. Regulation of prostatic growth and function by peptide growth factors. Prostate 1996, 28:392-405.
40. Scher H.I., Sawyers C.L. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen receptor signaling axis. J. Clin. Oncol. 2005, 23:8253-8261.
41. Lin H.K., Yeh S., Kang H.Y., Chang C. Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:7200-7205.
42. Orio F., Terouanne B., Georget V., Lumbroso S., Avances C., Siatka C., Sultan C. Potential action of IGF-I and EGF on androgen receptor nuclear transfer and transactivation in normal and cancer human prostate cell lines. Mol. Cell. Endocrinol. 2002, 198:105-114.
43. Rubinstein M., Idelman G., Plymate S.R., Narla G., Friedman S.L., Werner H. Transcriptional activation of the IGF-I receptor gene by the Kruppel-like factor-6 (KLF6) tumor suppressor protein: potential interactions between KLF6 and p53. Endocrinology 2004, 145:3769-3777.
44. Abramovitch S., Glaser T., Ouchi T., Werner H. BRCA1-Sp1 interactions in transcriptional regulation of the IGF-IR gene. FEBS Lett. 2003, 541:149-154.
45. Narla G., DiFeo A., Fernandez Y., Dhanasekaran S., Huang F., Sangodkar J., Hod E., Leake D., Friedman S.L., Hall S.J., Chinnaiyan A.M., Gerald W.L., Rubin M.A., Martignetti J.A. KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. J. Clin. Invest. 2008, 118:2711-2721.
46. Rosen E.M., Fan S., Goldberg I.D. BRCA1 and prostate cancer. Cancer Invest. 2001, 19:396-412.